Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1359379 | 0.95 | RAB9A (0.39) | ALDH1A1RAB9ANPC1PDE3BPDE3A | |
| SCHEMBL1358320 | 0.95 | ALDH1A1 (0.39) | ALDH1A1RAB9ASMN1; SMN2PKMCYP3A4 | |
| SCHEMBL1358259 | 0.90 | KDM1A (0.37) | CHEK1CYP3A4PARP1 | |
| SCHEMBL1359618 | 0.89 | CHEK1 (0.42) | PDK2CHEK1CYP3A4GAA | |
| SCHEMBL1360205 | 0.88 | KDM1A (0.38) | CYP3A4 | |
| SCHEMBL1357846 | 0.88 | HSP90AA1 (0.40) | CHEK1CYP3A4SMYD3GAA | |
| SCHEMBL1360466 | 0.88 | CHEK1 (0.37) | CHEK1CYP3A4SMYD3GAA | |
| SCHEMBL3144840 | 0.88 | CHEK1 (0.37) | CHEK1CYP3A4SMYD3GAA | |
| SCHEMBL1359564 | 0.87 | MAP4K4 (0.39) | PDK2CHEK1CYP3A4PARP1 | |
| SCHEMBL1359812 | 0.87 | KDM1A (0.39) | CHEK1CYP3A4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081658-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC | 2010-04-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081658-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, POLR2A, HCCS | PDK2 2000/4885ALDH1A1 1038/4885CHEK1 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.